Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Bioavailability Study of Lotiglipron in Healthy Men
NCT05652647Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lotiglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Pfizer. Primary endpoints: Total Recovery of Radioactivity in Urine, Feces and Both Routes Combined at 360 hours, Relative Abundance of [14C]PF-07081532 and Its Metabolites in Plasma and 1 more. Started Dec 2022; status: completed.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05652647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652647.